Showing 1 - 3 results of 3 for search '"Horsham, West Sussex"', query time: 0.06s Refine Results
  1. 1
    PO.5.102 Pharmacokinetic modelling of belimumab in patients with lupus nephritis: intravenous and subcutaneous loading dose regimen justification

    PO.5.102 Pharmacokinetic modelling of belimumab in patients with lupus nephritis: intravenous and subcutaneous loading dose regimen justification by Y Green, I Parodis, RA Levy, JA Gilbride, L Liefaard, C Henning, R Dimelow

    Published 2022-10-01
    Article
  2. 2
    Metabolomic Changes in Naturally MAP-Infected Holstein–Friesian Heifers Indicate Immunologically Related Biochemical Reprogramming

    Metabolomic Changes in Naturally MAP-Infected Holstein–Friesian Heifers Indicate Immunologically Related Biochemical Reprogramming by Emma N. Taylor, Manfred Beckmann, Bernardo Villarreal-Ramos, Hans-Martin Vordermeier, Glyn Hewinson, David Rooke, Luis A. J. Mur, Ad P. Koets

    Published 2021-10-01
    Get full text
    Article
  3. 3
    Bronchodilator efficacy and safety of indacaterol 150 µg once daily in patients with COPD: an analysis of pooled data

    Bronchodilator efficacy and safety of indacaterol 150 µg once daily in patients with COPD: an analysis of pooled data by Bleecker ER, Siler T, Owen R, Kramer B

    Published 2011-08-01
    “…Eugene R Bleecker1, Thomas Siler2, Roger Owen3, Benjamin Kramer41Center for Genomics and Personalized Medicine Research and Translational Medicine Institute, Wake Forest University Health Sciences, Winston-Salem, NC, USA; 2Midwest Chest Consultants, Saint Charles, MO, USA; 3Novartis Horsham Research Centre, Horsham, West Sussex, UK; 4Respiratory Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USABackground: Indacaterol is an inhaled, once-daily long-acting β2-agonist bronchodilator for regular use in patients with chronic obstructive pulmonary disease (COPD). …”
    Get full text
    Article

Search Tools: